Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ANI PHARMACEUTICALS INC

Get SEC filing alerts via email and in your feed for ANI PHARMACEUTICALS INC

ANIP

ANI PHARMACEUTICALS INC

About ANI PHARMACEUTICALS INC

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics. Key products include Purified Cortrophin® Gel for rare diseases and intravitreal implants ILUVIEN® and YUTIQ® for chronic retinal conditions. With a robust pipeline and recent acquisition of Alimera Sciences, ANI targets growth in rare diseases and generics, aiming to enhance patient care and expand its market presence globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from ANI PHARMACEUTICALS INC

1
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 20.5% Revenue Growth to $237.5 Million in Q1 2026

Via official filing (AI summary) | 28 days ago | 0 comments

2
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 43.8% Revenue Growth and Profitability Turnaround in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 53.6% Revenue Growth to $227.8 Million in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 53.1% Revenue Growth to $211.4 Million in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 43.4% Revenue Growth to $197.1 Million in Latest Quarter

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports $18.5 Million Net Loss Despite 26.2% Revenue Growth in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
ANI PHARMACEUTICALS INC ANI Pharmaceuticals Reports 12.5% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments